10602 results for 'CD19 antibody'

Cell Signalling · InflammationMAPK Signalling in Inflammatory Cytokine PathwaysMAPK cascades convert receptor engagement into changes in gene expression, and in inflammation they do it in both directi

PVR (Poliovirus receptor), also known as CD155, is a molecule that plays a dual role in regulating the immune response within the tumor microenvironment. While initially discovered as a r

Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses

Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest

Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day

V-domain Ig suppressor of T cell activation (VISTA) is an emerging immune checkpoint receptor that plays a key role in suppressing T cell activity within the tumor microenvironment (TME).

Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.

Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor

Quick Facts About VixarelimabWhat is Vixarelimab?Vixarelimab is an investigational monoclonal antibody developed to target oncostatin M receptor beta (OSMRβ), a key pathway involved in p

Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr

A macrophage does not decide to eat; it counts votes. Every particle it touches carries a mixture of pro-phagocytic and inhibitory ligands, and engulfment follows only when the activating tally clear

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease

The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.

The year 2026 has brought an unsettling spotlight onto an old adversary: Hantavirus. What began as isolated cases has rapidly escalated into a multi-country surge, leaving scientists and public healt

In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regu

Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor

Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression